:be Aktie

:be für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A3CWWB / ISIN: AT0000A2SGH0

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
02.06.2024 15:30:00

Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030

The pharmaceutical industry isn't the first place investors turn to when looking for high-growth stocks. However, some companies in the field look so promising that they could deliver well-above-average returns through the end of the decade.There are several candidates here, but two of the most attractive today are Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO). Read on to find out why these two giants could be the best performers in the industry through 2030.Eli Lilly and Novo Nordisk are rivals in the drug market for diabetes treatment, a competition that spans many decades. Over the years, the two players have continued to innovate, and the pharmaceutical giants are still at it. One of Eli Lilly's newer diabetes medicines is Mounjaro, first approved in the U.S. in May 2022. Mounjaro is a therapy with a novel mechanism of action that generated an $5 billion in sales last year, its first full year on the market.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Analysen zu :be AG Inhaber-Aktmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

:be AG Inhaber-Akt 0,25 25,00% :be AG Inhaber-Akt